[Current Advance in Targeted Treatment and Immunotherapy for BRAF-mutant 
Advanced Non-small Cell Lung Cancer]

Area of Science:

• Oncology
• Genetics
• Pharmacology

Background:

• Precision medicine advances have improved survival for advanced non-small cell lung cancer (NSCLC) patients by targeting driver genes.
• BRAF gene mutations are rare in NSCLC, and current treatment strategies often do not meet clinical needs.
• Targeted therapies are being developed for BRAF-mutated NSCLC, with a focus on both common (V600E) and rarer subtypes.

Purpose of the Study:

• To review the current progress in targeted therapy and immunotherapy for BRAF-mutated non-small cell lung cancer (NSCLC).
• To highlight the efficacy of existing treatments and the need for further research into novel therapeutic approaches for diverse BRAF mutation subtypes.

Main Methods:

• Literature review of recent studies on targeted therapy and immunotherapy in BRAF-mutated NSCLC.
• Analysis of clinical trial data and research findings on treatment efficacy across different BRAF mutation statuses (V600E and non-V600E).

Main Results:

• Targeted therapy has demonstrated significant efficacy in NSCLC patients with BRAF V600E mutations.
• Immunotherapy has shown positive antitumor activity in both BRAF V600E and non-V600E mutated NSCLC.
• Ongoing research aims to identify and optimize targeted therapies for other BRAF-mutated subtypes.

Conclusions:

• Targeted therapy and immunotherapy represent important treatment modalities for BRAF-mutated NSCLC.
• Further investigation is crucial to develop more effective and personalized treatment strategies for all BRAF-mutated NSCLC patients.